Healthcare / Drug Manufacturers - GeneralMilan
$190.76
-3.70 (-1.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $18.1B · quality 80.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$459.2B
P/E
25.7x
↑EV/EBITDA
12.0x
↓ROE
32.9%
↑Gross Margin
67.9%
↑Debt/Equity
0.59
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.6%
FCF CAGR
+4.0%
FCF margin
20.5%
FCF / Net income
0.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $94.19B · net income $26.80B · FCF $19.31B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $94.19B | $94.19B | $88.82B | $85.16B | $79.99B |
| Net Income | $26.80B | $26.80B | $14.07B | $35.15B | $17.94B |
| EBITDA | $41.05B | $41.05B | $24.78B | $23.32B | $26.61B |
| EPS | 11.03 | 11.03 | 5.79 | 13.72 | 6.73 |
| Gross Margin | 67.9% | 67.9% | 69.1% | 68.8% | 69.3% |
| Operating Margin | 27.2% | 27.2% | 23.9% | 25.8% | 26.3% |
| Net Margin | 28.5% | 28.5% | 15.8% | 41.3% | 22.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.59 | 0.59 | 0.51 | 0.43 | 0.52 |
| Current Ratio | 1.02 | 1.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $19.31B | $19.31B | $18.06B | $17.78B | $17.18B |
| Returns | |||||
| ROE | 32.9% | 32.9% | 19.7% | 51.1% | 23.4% |
| Valuation | |||||
| P/E | 25.74 | 25.74 | 24.21 | 10.69 | — |
| EV/EBITDA | 11.98 | 11.98 | 14.25 | 16.43 | — |
| P/B | 5.68 | 5.68 | 4.76 | 5.46 | — |
| Growth & Yield | |||||
| Revenue Growth | 6.0% | 6.0% | 4.3% | 6.5% | — |
| EPS Growth | 90.5% | 90.5% | -57.8% | 103.9% | — |
| Dividend Yield | 2.4% | 2.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.3%
EPS terminal req.
$16.93
Spread vs growth
75.2%
5Y implied EPS CAGR
13.2%
EPS terminal req.
$20.48
Spread vs growth
77.3%
10Y implied EPS CAGR
11.6%
EPS terminal req.
$32.99
Spread vs growth
78.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+43.9%
Start / end P/E
23.3x → 17.3x
EPS bridge
5.79 → 11.03
Residual
-23.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.